Dr. Preston D. Steen

About Preston D. Steen

Education:

• Obtained MD from the University of North Dakota School of Medicine & Health Sciences (2015).
• Completed Residency in Internal Medicine at the University of Minnesota Medical Center (2018).
• Finished Fellowship in Hematology/Oncology at the Mayo Clinic, Rochester, Minnesota (2021).

Experience:

• Currently practices as a hematologist and oncologist at Sanford Roger Maris Cancer Center.
• Specializes in internal medicine, hematology, and oncology.

Area of expertise

Affiliated Hospitals

Sanford Roger Maris Cancer Center

Sanford Bismarck Medical Center

Clinical Trials Preston D. Steen is currently running

Stereotactic Radiation + Immunotherapy

for Kidney Cancer

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.

Recruiting1 award Phase 221 criteria

Lomustine + Standard Therapy

for Glioblastoma

This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Adding lomustine to usual treatment of temozolomide and radiation therapy may help shrink and stabilize glioblastoma.

Recruiting2 awards Phase 34 criteria

More about Preston D. Steen

Other Doctors you might be interested in

Frequently asked questions